Energy metabolism defects in Huntington's disease and effects of coenzyme Q10

Annals of Neurology

Volumn 41, Issue 2, 1997, Pages 160-165

  Koroshetz, Walter J ^a   Jenkins, Bruce G ^a   Rosen, Bruce R ^a   Flint Beal, M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE PHOSPHATE; LACTIC ACID; PHOSPHATE; PYRUVIC ACID; UBIQUINONE;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; METABOLIC DISORDER; ORAL DRUG ADMINISTRATION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

AGED; ENERGY METABOLISM; HUMANS; HUNTINGTON DISEASE; MIDDLE AGED; PROGNOSIS; UBIQUINONE;

EID: 0031044805     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410410206     Document Type: Article

References (35)

1. The Huntington's Disease Collaborative Research Group. The novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983
2. Strong TV, Tagle DA, Valdes JM, et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissue. Nat Genet 1993;5:259-265
3. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119-130
4. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992;42:733-738
5. Burke JR, Enghild JJ, Martin ME, et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 1996;2:347-350
6. Jenkins B, Koroshetz W, Beal MF, Rosen B. Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy. Neurology 1993;43:2689-2695
7. Marbach EP, Weil MH. Rapid enzymatic measurement of blood lactate and pyruvate. Use and significance of metaphosphoric acid as a common precipitant. Clin Chem 1967;13:314-325
8. Ellison DW, Beal MF, Martin JB. Amino acid neurotransmitters in postmortem human brain analyzed by high performance liquid chromatography with electrochemical detection. J Neurosci Methods 1987;19:305-315
9. O'Brien CF, Miller C, Goldblatt D, et al. Extraneural metabolism in early Huntington's disease. Ann Neurol 1990:28:300-301
10. Myers RH, Sax DS, Koroshetz WJ, et al. Factors associated with slow progression in Huntington's disease. Arch Neurol 1991;48:800-804
11. Gu M, Gash MT, Mann VM, et al. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 1996;39:385-389
12. Brouillet E, Hantraye P, Ferrante RJ, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 1995;92:7105-7109
13. 31P MRS) in neuromuscular disorders. Ann Neurol 1991;30:90-97
14. Matthews PM, Allaire C, Shoubridge EA, et al. In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology 1991;41:114-120
15. Penn AMW, Roberts T, Hodder J, et al. Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology 1995;45:2097-2099
16. 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease. J Neurol Sci 1994;125:77-81
17. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology 1992;42:1203-1208
18. Robinson BH, Glerum DM, Chow W, et al. The use of skin fibroblast cultures in the detection of respiratory chain defects in patients with lactic acidemia. Pediatr Res 1990;28:549-555
19. Abe K, Fujimura H, Nishikawa Y, et al. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Scand 1991;83:356-359
20. Borud O, Torbergsen T, Mathiesen E. Increased lactate in cerebrospinal fluid from 7 siblings in a family with mitochondrial myopathy and cerebellar ataxia. J Inherit Metab Dis 1987;10:400
21. Matsuishi T, Sakai T, Naito E, et al. Elevated cerebrospinal fluid lactate/pyruvate ratio in Machado-Joseph disease. Acta Neurol Scand 1996;93:72-75
22. Bruck J, Gerstenbrand F, Gnad H, et al. On changes in the composition of cerebrospinal fluid in the choreatic syndrome. J Neurol Sci 1967;5:257-265
23. Carter CJ. Increased alanine aminotransferase activity in the Huntington's disease putamen. J Neurol Sci 1984:66:27-32
24. Kunishita T, Vaswani KK, Morrow CR, et al. Ethanolamine kinase activity in purified myelin of rat brain. J Neurochem 1987;48:1-7
25. Lenaz G. Role of mobility of redox components in the inner mitochondrial membrane. J Membr Biol 1988;104:193-209
26. Schneider H, Lemaster JJ, Hackembroek CR. Lateral diffusion of ubiquinone during electron transfer in phospholipid- and ubiquinone-enriched mitochondrial membrane. J Biol Chem 1982;257:10789-10793
27. Beyer RE. An analysis of the role of coenzyme Q in free radical generation and as an antioxidant. Biochem Cell Biol 1992;70:390-403
28. 10 in a patient with mitochondrial encephalomyopathy. J Neurol 1987;2344:62-63
29. 10 administration. J Neurol Neurosurg Psychiatry 1987;50:1475-1481
30. 10. Neurology 1988;38:892-899
31. 10. Neurology 1986;36:45-53
32. 10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993;43:884-890
33. 10 tolerability in Humington's disease. Mov Disord 1996;11:321-323
34. Favit A, Nicoletti F, Scapagnini U, Canonico PL. Ubiquinone protects cultured neurons against spontaneous and excitotoxin-induced degeneration. J Cereb Blood Flow Metab 1992;12:638-645
35. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 1994;36:882-888